IONS · Ionis Pharmaceuticals Inc
$57.24
+1.37 (+2.45%)
At close · Aug 14
Market Cap
$9.51B
Shares
166.18M
Ionis Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Ionis Pharmaceuticals Inc (IONS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲20%
$159.77M
−$46.99M
'22 Q3
22-11-14
▼65.5%
$151.89M
−$52.43M
'22 Q4
23-02-22
▼8%
$130.52M
−$124.32M
'23 Q1
23-05-03
▲40.8%
$188.41M
−$85.29M
'23 Q2
23-08-09
▼9.7%
$144.21M
−$147.41M
'23 Q3
23-11-02
▲113.6%
$324.50M
−$9.26M
'23 Q4
24-02-21
▼8.4%
$119.50M
−$142.80M
'24 Q1
24-05-07
▲19.6%
$225.25M
−$66.27M
'24 Q2
24-08-01
▼7.2%
$133.81M
−$140.48M
'24 Q3
24-11-06
▼30.2%
$226.58M
−$104.35M
'24 Q4
25-02-19
▲10.1%
$131.61M
−$146.94M
'25 Q1
25-04-30
▲100.7%
$452.05M
$123.55M
'25 Q2
25-07-30
▲17.1%
$156.72M
−$128.61M
'25 Q3
25-10-29
▼10.3%
$203.33M
−$229.39M
'25 Q4
26-02-25
▲87%
$246.09M
−$92.53M
'26 Q1
26-04-29
LATEST
▼40.7%
$267.95M
−$114.65M
'26 Q2
26-07-29
Earnings call
FY26 · Q2
2026-07-29
Second Quarter 2026 Financial Results Webcast
Positive tone
Tringolza (Tryngolza) SHTG launch
Eplontersin ATTR cardiomyopathy Phase 3 disappointment
Tringolza FCS commercial execution
Revenue
$267.95M
▼ 40.7% YoY Diluted EPS
$-0.69
▼ 198.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
Ionis Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone
Tryngolza (olezarsen FCS) launch momentum
DAWNZERA (donidalorsen) launch in HAE
Olezarsen SHTG launch preparation and peak sales raise
Revenue
$246.09M
▲ 87% YoY Diluted EPS
$-0.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Ionis Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone
Olezarsen in severe hypertriglyceridemia
DAWNZERA launch in HAE
TRYNGOLZA launch and FCS franchise
Revenue
$203.33M
▼ 10.3% YoY Diluted EPS
$-1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Ionis Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone
Tringolza launch (FCS)
Olezarsen (olazarsen/olisarcin) in SHTG
Donzara / HAE launch
Revenue
$156.72M
▲ 17.1% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Ionis Pharmaceuticals Inc Q2 FY2025 Earnings Call
Confident tone
Donidalorsen approval and HAE launch preparation
CORE1/CORE2 acute pancreatitis readout risk
Olezarsen severe hypertriglyceridemia opportunity
Revenue
$452.05M
▲ 100.7% YoY Diluted EPS
$0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Ionis Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone
TRYNGOLZA (olezarsen/FCS) launch
donidalorsen / hereditary angioedema (HAE)
Raised 2025 financial guidance
Revenue
$131.61M
▲ 10.1% YoY Diluted EPS
$-0.93
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
Ionis Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone
Tringolza independent launch in FCS
Pipeline of independent launches
Olezarsen SHTG opportunity
Revenue
$226.58M
▼ 30.2% YoY Diluted EPS
$-0.66
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Ionis Pharmaceuticals Inc Q3 FY2024 Earnings Call
Confident tone
Olezarsen launch and FCS approval
ION582 / Angelman syndrome program
Donidalorsen for HAE
Revenue
$133.81M
▼ 7.2% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ionis Pharmaceuticals Inc Q2 FY2024 Earnings Call
Confident tone
WAINUA launch and global expansion
Olezarsen for FCS and sHTG
QALSODY availability and ALS
Revenue
$225.25M
▲ 19.6% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ionis Pharmaceuticals Inc Q1 FY2024 Earnings Call
Confident tone
Olezarsen for FCS and SHTG
Donidalorsen for HAE
ION224 / DGAT2 for MASH and partnering
Revenue
$119.50M
▼ 8.4% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
Ionis Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone
WAINUA launch and ATTR franchise
Donidalorsen for HAE
Olezarsen for FCS
Revenue
$324.50M
▲ 113.6% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Ionis Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$144.21M
▼ 9.7% YoY Diluted EPS
$-1.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Ionis Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$188.41M
▲ 40.8% YoY Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Ionis Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$130.52M
▼ 8% YoY Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Ionis Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$151.89M
▼ 65.5% YoY Diluted EPS
$-0.37
▼ 126.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Ionis Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$159.77M
▲ 20% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Ionis Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$133.79M
▲ 6.4% YoY Diluted EPS
$-0.74
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Ionis Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$141.92M
▲ 27.2% YoY Diluted EPS
$-0.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Ionis Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$440.01M
▲ 51.6% YoY Diluted EPS
$1.41
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Ionis Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$133.09M
▼ 16.9% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Ionis Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$125.75M
▼ 13.6% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Ionis Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$111.61M
▼ 16.3% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Ionis Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$290.28M
▼ 41.2% YoY Diluted EPS
$-2.54
▼ 298.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Ionis Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$160.08M
▼ 4.7% YoY Diluted EPS
$-0.18
▼ 200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Ionis Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$145.54M
▼ 11.2% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ionis Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$133.37M
▼ 55.1% YoY Diluted EPS
$-0.28
▼ 145.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-26
Ionis Pharmaceuticals Inc Q4 FY2019 Earnings Call
Revenue
$493.68M
▲ 157% YoY Diluted EPS
$1.28
▼ 42.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
874015
CUSIP
462222100
13F (30d)
498 filings
470 filers
Visit website
Investor relations